Repeated Piperacillin-Tazobactam Plasma Concentration Measurements in Severely Obese Versus Nonobese Critically Ill Septic Patients and the Risk of Under–and …

B Jung, M Mahul, D Breilh, R Legeron… - Critical care …, 2017 - journals.lww.com
Objective: Obesity and critical illness modify pharmacokinetics of antibiotics, but piperacillin-
tazobactam continuous IV infusion pharmacokinetics has been poorly studied in obese …
被引用次数：28 相关文章

Repeated Piperacillin-Tazobactam Plasma Concentration Measurements in Severely Obese Versus Nonobese Critically Ill Septic Patients and the Risk of Under–and …

B Jung, M Mahul, D Breilh, R Legeron, J Signe… - core.ac.uk
Repeated Piperacillin-Tazobactam Plasma Concentration Measurements in Severely
Obese Versus Nonobese Critically Ill Septic Patie Page 1 HAL Id: hal-01779526 https://hal.archives-ouvertes.fr/hal-01779526 …

Repeated Piperacillin-Tazobactam Plasma Concentration Measurements in Severely Obese Versus Nonobese Critically Ill Septic Patients and the Risk of Under–and …

B Jung, M Mahul, D Breilh, R Legeron, J Signe… - Critical Care …, 2017 - hal.science
Obesity and critical illness modify pharmacokinetics of antibiotics, but piperacillin-
tazobactam continuous IV infusion pharmacokinetics has been poorly studied in obese …

Repeated Piperacillin-Tazobactam Plasma Concentration Measurements in Severely Obese Versus Nonobese Critically Ill Septic Patients and the Risk of Under-and …

B Jung, M Mahul, D Breilh, R Legeron… - Critical care …, 2017 - pubmed.ncbi.nlm.nih.gov
Objective Obesity and critical illness modify pharmacokinetics of antibiotics, but piperacillin-
tazobactam continuous IV infusion pharmacokinetics has been poorly studied in obese …

Repeated Piperacillin-Tazobactam Plasma Concentration Measurements in Severely Obese Versus Nonobese Critically Ill Septic Patients and the Risk of Under-and …

B Jung, M Mahul, D Breilh, R Legeron, J Signe… - Critical Care …, 2017 - europepmc.org
Objective Obesity and critical illness modify pharmacokinetics of antibiotics, but piperacillin-
tazobactam continuous IV infusion pharmacokinetics has been poorly studied in obese …

Repeated Piperacillin-Tazobactam Plasma Concentration Measurements in Severely Obese Versus Nonobese Critically Ill Septic Patients and the Risk of Under–and …

B Jung, M Mahul, D Breilh, R Legeron… - Critical Care …, 2017 - ingentaconnect.com
Objective: Obesity and critical illness modify pharmacokinetics of antibiotics, but piperacillin-
tazobactam continuous IV infusion pharmacokinetics has been poorly studied in obese …
[PDF] researchgate.net

[PDF][PDF] Repeated Piperacillin-Tazobactam Plasma Concentration Measurements in Severely Obese Versus Nonobese Critically Ill Septic Patients and the Risk of …

2017 - researchgate.net
Objective: Obesity and critical illness modify pharmacokinetics of antibiotics, but piperacillin-
tazobactam continuous IV infusion pharmacokinetics has been poorly studied in obese …

Repeated piperacillin-tazobactam plasma concentration measurements in severely obese versus nonobese critically ill septic patients and the risk of under-and …

B Jung, M Mahul, D Breilh, R Legeron, J Signe… - 2017 - cabidigitallibrary.org
Objective: Obesity and critical illness modify pharmacokinetics of antibiotics, but piperacillin-
tazobactam continuous IV infusion pharmacokinetics has been poorly studied in obese …

Repeated Piperacillin-Tazobactam Plasma Concentration Measurements in Severely Obese Versus Nonobese Critically Ill Septic Patients and the Risk of Under–and …

B Jung, M Mahul, D Breilh, R Legeron, J Signe… - hal.science
Repeated Piperacillin-Tazobactam Plasma Concentration Measurements in Severely Obese
Versus Nonobese Critically Ill Septic Patie Page 1 HAL Id: hal-01779526 https://hal.science/hal-01779526 …